SK18312002A3 - Derivát alebo analóg kyseliny pamoovej, spôsob jeho prípravy, farmaceutický prostriedok, diagnostická súprava a použitie - Google Patents

Derivát alebo analóg kyseliny pamoovej, spôsob jeho prípravy, farmaceutický prostriedok, diagnostická súprava a použitie Download PDF

Info

Publication number: SK18312002A3
Authority: SK; Slovakia
Prior art keywords: compound; formula; compounds; naphthyl; chloride
Prior art date: 2000-06-23

Application number

SK1831-2002A

Other languages

English (en)

Slovak (sk)

Inventor

Maria Grazia Gallo

Maria Grazia Cima

Fabrizio Giorgi

Maria Ornella Tinti

Paola Piovesan

Orlando Ghirardi

Original Assignee

Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-06-23

Filing date

2001-06-15

Publication date

2003-06-03

2001-06-15 Application filed by Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. filed Critical Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.

2003-06-03 Publication of SK18312002A3 publication Critical patent/SK18312002A3/sk

Links

201000010099 disease Diseases 0.000 title claims abstract description 25
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 25
238000002360 preparation method Methods 0.000 title claims abstract description 19
WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 title claims abstract description 11
238000011282 treatment Methods 0.000 title claims abstract description 11
239000003814 drug Substances 0.000 title claims abstract description 9
150000003839 salts Chemical class 0.000 claims abstract description 7
150000001875 compounds Chemical class 0.000 claims description 61
238000000034 method Methods 0.000 claims description 22
229910052757 nitrogen Inorganic materials 0.000 claims description 17
125000000217 alkyl group Chemical group 0.000 claims description 14
-1 {1 - [(2-hydroxy-1-naphthyl) methyl] -2-naphthyl} oxy Chemical group 0.000 claims description 14
206010002022 amyloidosis Diseases 0.000 claims description 13
239000003795 chemical substances by application Substances 0.000 claims description 13
230000008569 process Effects 0.000 claims description 12
125000004432 carbon atom Chemical group C* 0.000 claims description 11
230000002285 radioactive effect Effects 0.000 claims description 11
239000002904 solvent Substances 0.000 claims description 10
208000024827 Alzheimer disease Diseases 0.000 claims description 9
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
230000008021 deposition Effects 0.000 claims description 8
229920006395 saturated elastomer Polymers 0.000 claims description 8
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 7
229910052799 carbon Inorganic materials 0.000 claims description 7
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 7
229910052739 hydrogen Inorganic materials 0.000 claims description 7
230000002140 halogenating effect Effects 0.000 claims description 6
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
239000000203 mixture Substances 0.000 claims description 6
125000000896 monocarboxylic acid group Chemical group 0.000 claims description 6
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 5
125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 claims description 5
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 4
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
239000002253 acid Substances 0.000 claims description 4
230000002378 acidificating effect Effects 0.000 claims description 4
150000001263 acyl chlorides Chemical class 0.000 claims description 4
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
238000003745 diagnosis Methods 0.000 claims description 4
229910052738 indium Inorganic materials 0.000 claims description 4
APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 claims description 4
229910052740 iodine Inorganic materials 0.000 claims description 4
229910052760 oxygen Inorganic materials 0.000 claims description 4
239000001301 oxygen Substances 0.000 claims description 4
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
238000003756 stirring Methods 0.000 claims description 4
CNPURSDMOWDNOQ-UHFFFAOYSA-N 4-methoxy-7h-pyrrolo[2,3-d]pyrimidin-2-amine Chemical compound COC1=NC(N)=NC2=C1C=CN2 CNPURSDMOWDNOQ-UHFFFAOYSA-N 0.000 claims description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
229910052688 Gadolinium Inorganic materials 0.000 claims description 3
229960000583 acetic acid Drugs 0.000 claims description 3
150000001299 aldehydes Chemical class 0.000 claims description 3
125000003545 alkoxy group Chemical group 0.000 claims description 3
125000003282 alkyl amino group Chemical group 0.000 claims description 3
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 3
238000012631 diagnostic technique Methods 0.000 claims description 3
125000004663 dialkyl amino group Chemical group 0.000 claims description 3
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 3
UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 claims description 3
239000001257 hydrogen Substances 0.000 claims description 3
125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 3
239000008194 pharmaceutical composition Substances 0.000 claims description 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
229910052713 technetium Inorganic materials 0.000 claims description 3
GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 claims description 3
206010008111 Cerebral haemorrhage Diseases 0.000 claims description 2
201000010374 Down Syndrome Diseases 0.000 claims description 2
241000287828 Gallus gallus Species 0.000 claims description 2
ZMANZCXQSJIPKH-UHFFFAOYSA-N N,N-Diethylethanamine Substances CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 2
206010044688 Trisomy 21 Diseases 0.000 claims description 2
239000004480 active ingredient Substances 0.000 claims description 2
150000001350 alkyl halides Chemical class 0.000 claims description 2
208000037976 chronic inflammation Diseases 0.000 claims description 2
230000006020 chronic inflammation Effects 0.000 claims description 2
239000007822 coupling agent Substances 0.000 claims description 2
239000003085 diluting agent Substances 0.000 claims description 2
239000012362 glacial acetic acid Substances 0.000 claims description 2
125000006239 protecting group Chemical group 0.000 claims description 2
YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 claims description 2
102000029797 Prion Human genes 0.000 claims 2
108091000054 Prion Proteins 0.000 claims 2
229910052751 metal Inorganic materials 0.000 claims 2
239000002184 metal Substances 0.000 claims 2
208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 1
208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 1
208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 1
238000009007 Diagnostic Kit Methods 0.000 claims 1
208000003736 Gerstmann-Straussler-Scheinker Disease Diseases 0.000 claims 1
241001494479 Pecora Species 0.000 claims 1
FMOFZDRJQGVLEL-UHFFFAOYSA-N [Cl-].CC(C([NH3+])(C)C)CC=O Chemical compound [Cl-].CC(C([NH3+])(C)C)CC=O FMOFZDRJQGVLEL-UHFFFAOYSA-N 0.000 claims 1
150000001412 amines Chemical class 0.000 claims 1
125000003277 amino group Chemical group 0.000 claims 1
206010012601 diabetes mellitus Diseases 0.000 claims 1
239000003937 drug carrier Substances 0.000 claims 1
239000004922 lacquer Substances 0.000 claims 1
210000004698 lymphocyte Anatomy 0.000 claims 1
238000002603 single-photon emission computed tomography Methods 0.000 claims 1
159000000000 sodium salts Chemical class 0.000 claims 1
125000001424 substituent group Chemical group 0.000 claims 1
239000013589 supplement Substances 0.000 claims 1
108090000765 processed proteins & peptides Proteins 0.000 description 26
YGLLICRFEVEWOZ-UHFFFAOYSA-L disodium;3-carboxy-1-[(3-carboxy-2-oxidonaphthalen-1-yl)methyl]naphthalen-2-olate Chemical compound [Na+].[Na+].C1=CC=C2C(CC3=C4C=CC=CC4=CC(=C3O)C([O-])=O)=C(O)C(C([O-])=O)=CC2=C1 YGLLICRFEVEWOZ-UHFFFAOYSA-L 0.000 description 25
239000011734 sodium Substances 0.000 description 14
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 13
239000000243 solution Substances 0.000 description 13
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 12
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
229910052708 sodium Inorganic materials 0.000 description 12
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 8
230000006907 apoptotic process Effects 0.000 description 8
239000007787 solid Substances 0.000 description 8
108010090849 Amyloid beta-Peptides Proteins 0.000 description 7
102000013455 Amyloid beta-Peptides Human genes 0.000 description 7
210000004027 cell Anatomy 0.000 description 7
230000000694 effects Effects 0.000 description 7
239000000835 fiber Substances 0.000 description 7
230000009467 reduction Effects 0.000 description 7
210000002966 serum Anatomy 0.000 description 7
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
241000700159 Rattus Species 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
230000006378 damage Effects 0.000 description 6
239000000523 sample Substances 0.000 description 6
210000004556 brain Anatomy 0.000 description 5
238000002474 experimental method Methods 0.000 description 5
238000011534 incubation Methods 0.000 description 5
238000004519 manufacturing process Methods 0.000 description 5
239000000047 product Substances 0.000 description 5
ZPANWZBSGMDWON-UHFFFAOYSA-N 1-[(2-hydroxynaphthalen-1-yl)methyl]naphthalen-2-ol Chemical compound C1=CC=C2C(CC3=C4C=CC=CC4=CC=C3O)=C(O)C=CC2=C1 ZPANWZBSGMDWON-UHFFFAOYSA-N 0.000 description 4
238000005481 NMR spectroscopy Methods 0.000 description 4
HQOLZZWNPROYNV-FYZOBXCZSA-N acetyl chloride;(3r)-3-hydroxy-4-(trimethylazaniumyl)butanoate Chemical compound CC(Cl)=O.C[N+](C)(C)C[C@H](O)CC([O-])=O HQOLZZWNPROYNV-FYZOBXCZSA-N 0.000 description 4
230000002490 cerebral effect Effects 0.000 description 4
239000008187 granular material Substances 0.000 description 4
239000002609 medium Substances 0.000 description 4
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
230000001537 neural effect Effects 0.000 description 4
210000002569 neuron Anatomy 0.000 description 4
230000002265 prevention Effects 0.000 description 4
239000000126 substance Substances 0.000 description 4
238000012360 testing method Methods 0.000 description 4
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
102000004142 Trypsin Human genes 0.000 description 3
108090000631 Trypsin Proteins 0.000 description 3
210000001218 blood-brain barrier Anatomy 0.000 description 3
239000012043 crude product Substances 0.000 description 3
238000011156 evaluation Methods 0.000 description 3
230000001965 increasing effect Effects 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
230000002887 neurotoxic effect Effects 0.000 description 3
102000004196 processed proteins & peptides Human genes 0.000 description 3
230000000750 progressive effect Effects 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
239000011541 reaction mixture Substances 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
230000000946 synaptic effect Effects 0.000 description 3
231100000419 toxicity Toxicity 0.000 description 3
230000001988 toxicity Effects 0.000 description 3
239000012588 trypsin Substances 0.000 description 3
JWAZRIHNYRIHIV-UHFFFAOYSA-N 2-naphthol Chemical compound C1=CC=CC2=CC(O)=CC=C21 JWAZRIHNYRIHIV-UHFFFAOYSA-N 0.000 description 2
102000009091 Amyloidogenic Proteins Human genes 0.000 description 2
108010048112 Amyloidogenic Proteins Proteins 0.000 description 2
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
108010002352 Interleukin-1 Proteins 0.000 description 2
108090001005 Interleukin-6 Proteins 0.000 description 2
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
206010029350 Neurotoxicity Diseases 0.000 description 2
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
206010044221 Toxic encephalopathy Diseases 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
230000009471 action Effects 0.000 description 2
230000003213 activating effect Effects 0.000 description 2
230000003942 amyloidogenic effect Effects 0.000 description 2
230000003110 anti-inflammatory effect Effects 0.000 description 2
125000004429 atom Chemical group 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
230000008499 blood brain barrier function Effects 0.000 description 2
210000005013 brain tissue Anatomy 0.000 description 2
230000004094 calcium homeostasis Effects 0.000 description 2
210000003710 cerebral cortex Anatomy 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical group [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 description 2
230000001054 cortical effect Effects 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
230000007850 degeneration Effects 0.000 description 2
229940079593 drug Drugs 0.000 description 2
230000028023 exocytosis Effects 0.000 description 2
230000002518 glial effect Effects 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
230000007062 hydrolysis Effects 0.000 description 2
238000006460 hydrolysis reaction Methods 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
230000002757 inflammatory effect Effects 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
238000011835 investigation Methods 0.000 description 2
ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
239000012528 membrane Substances 0.000 description 2
230000004060 metabolic process Effects 0.000 description 2
230000035772 mutation Effects 0.000 description 2
230000009223 neuronal apoptosis Effects 0.000 description 2
230000000324 neuroprotective effect Effects 0.000 description 2
231100000228 neurotoxicity Toxicity 0.000 description 2
230000007135 neurotoxicity Effects 0.000 description 2
239000012074 organic phase Substances 0.000 description 2
230000001575 pathological effect Effects 0.000 description 2
239000012071 phase Substances 0.000 description 2
239000008363 phosphate buffer Substances 0.000 description 2
238000002600 positron emission tomography Methods 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
KFWJVABDRRDUHY-XJQYZYIXSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1.C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 KFWJVABDRRDUHY-XJQYZYIXSA-N 0.000 description 1
NKTAFVCXHYXTQK-UHFFFAOYSA-N 1,1,1-trichloro-3-methylbutane Chemical compound CC(C)CC(Cl)(Cl)Cl NKTAFVCXHYXTQK-UHFFFAOYSA-N 0.000 description 1
238000005160 1H NMR spectroscopy Methods 0.000 description 1
229940100578 Acetylcholinesterase inhibitor Drugs 0.000 description 1
208000000044 Amnesia Diseases 0.000 description 1
102000001049 Amyloid Human genes 0.000 description 1
108010094108 Amyloid Proteins 0.000 description 1
102000014303 Amyloid beta-Protein Precursor Human genes 0.000 description 1
108010079054 Amyloid beta-Protein Precursor Proteins 0.000 description 1
206010059245 Angiopathy Diseases 0.000 description 1
101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 description 1
241000238557 Decapoda Species 0.000 description 1
101710088194 Dehydrogenase Proteins 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
101100117236 Drosophila melanogaster speck gene Proteins 0.000 description 1
GKQLYSROISKDLL-UHFFFAOYSA-N EEDQ Chemical compound C1=CC=C2N(C(=O)OCC)C(OCC)C=CC2=C1 GKQLYSROISKDLL-UHFFFAOYSA-N 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
229940126544 HIV-1 protease inhibitor Drugs 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
108090000604 Hydrolases Proteins 0.000 description 1
102000004157 Hydrolases Human genes 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
102100023915 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
108090001007 Interleukin-8 Proteins 0.000 description 1
108010063738 Interleukins Proteins 0.000 description 1
102000015696 Interleukins Human genes 0.000 description 1
206010051602 Laziness Diseases 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
241000207836 Olea <angiosperm> Species 0.000 description 1
101150023107 PS2 gene Proteins 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
102100024078 Plasma serine protease inhibitor Human genes 0.000 description 1
101710183733 Plasma serine protease inhibitor Proteins 0.000 description 1
208000024777 Prion disease Diseases 0.000 description 1
239000004365 Protease Substances 0.000 description 1
239000005700 Putrescine Substances 0.000 description 1
AQXXZDYPVDOQEE-MXDQRGINSA-N Pyrantel pamoate Chemical compound CN1CCCN=C1\C=C\C1=CC=CS1.C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 AQXXZDYPVDOQEE-MXDQRGINSA-N 0.000 description 1
LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
208000012936 Sheep disease Diseases 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
XARHIGDFPPYRPM-UHFFFAOYSA-N [Cl-].[NH3+]CC=O Chemical compound [Cl-].[NH3+]CC=O XARHIGDFPPYRPM-UHFFFAOYSA-N 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
239000012346 acetyl chloride Substances 0.000 description 1
230000004913 activation Effects 0.000 description 1
208000038016 acute inflammation Diseases 0.000 description 1
230000006022 acute inflammation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
VLSMHEGGTFMBBZ-UHFFFAOYSA-N alpha-Kainic acid Natural products CC(=C)C1CNC(C(O)=O)C1CC(O)=O VLSMHEGGTFMBBZ-UHFFFAOYSA-N 0.000 description 1
230000004075 alteration Effects 0.000 description 1
108010061598 amyloid beta-protein (25-35) Proteins 0.000 description 1
230000006933 amyloid-beta aggregation Effects 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
229940124339 anthelmintic agent Drugs 0.000 description 1
239000000921 anthelmintic agent Substances 0.000 description 1
230000001455 anti-clotting effect Effects 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
229940124599 anti-inflammatory drug Drugs 0.000 description 1
239000003080 antimitotic agent Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
210000002565 arteriole Anatomy 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
238000010533 azeotropic distillation Methods 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
230000003542 behavioural effect Effects 0.000 description 1
229950011260 betanaphthol Drugs 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000030833 cell death Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
230000001713 cholinergic effect Effects 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000002983 circular dichroism Methods 0.000 description 1
238000005352 clarification Methods 0.000 description 1
230000007012 clinical effect Effects 0.000 description 1
230000003920 cognitive function Effects 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000004737 colorimetric analysis Methods 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
239000013068 control sample Substances 0.000 description 1
TVZPLCNGKSPOJA-UHFFFAOYSA-N copper zinc Chemical compound [Cu].[Zn] TVZPLCNGKSPOJA-UHFFFAOYSA-N 0.000 description 1
210000004292 cytoskeleton Anatomy 0.000 description 1
230000010013 cytotoxic mechanism Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000003412 degenerative effect Effects 0.000 description 1
238000010217 densitometric analysis Methods 0.000 description 1
230000002999 depolarising effect Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
230000009429 distress Effects 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
230000005284 excitation Effects 0.000 description 1
210000001723 extracellular space Anatomy 0.000 description 1
239000004744 fabric Substances 0.000 description 1
230000004720 fertilization Effects 0.000 description 1
239000012530 fluid Substances 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
239000012634 fragment Substances 0.000 description 1
230000008717 functional decline Effects 0.000 description 1
230000000848 glutamatergic effect Effects 0.000 description 1
239000007986 glycine-NaOH buffer Substances 0.000 description 1
230000002218 hypoglycaemic effect Effects 0.000 description 1
230000002055 immunohistochemical effect Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
230000037456 inflammatory mechanism Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000007689 inspection Methods 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
230000003993 interaction Effects 0.000 description 1
229940047122 interleukins Drugs 0.000 description 1
210000001153 interneuron Anatomy 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
239000011630 iodine Substances 0.000 description 1
VLSMHEGGTFMBBZ-OOZYFLPDSA-N kainic acid Chemical compound CC(=C)[C@H]1CN[C@H](C(O)=O)[C@H]1CC(O)=O VLSMHEGGTFMBBZ-OOZYFLPDSA-N 0.000 description 1
229950006874 kainic acid Drugs 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
201000010901 lateral sclerosis Diseases 0.000 description 1
230000007774 longterm Effects 0.000 description 1
231100000863 loss of memory Toxicity 0.000 description 1
230000001926 lymphatic effect Effects 0.000 description 1
230000002132 lysosomal effect Effects 0.000 description 1
210000003712 lysosome Anatomy 0.000 description 1
230000001868 lysosomic effect Effects 0.000 description 1
210000001161 mammalian embryo Anatomy 0.000 description 1
230000003340 mental effect Effects 0.000 description 1
238000001531 micro-dissection Methods 0.000 description 1
210000000274 microglia Anatomy 0.000 description 1
230000002025 microglial effect Effects 0.000 description 1
208000005264 motor neuron disease Diseases 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
230000008035 nerve activity Effects 0.000 description 1
210000000944 nerve tissue Anatomy 0.000 description 1
230000004770 neurodegeneration Effects 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
230000016273 neuron death Effects 0.000 description 1
231100000189 neurotoxic Toxicity 0.000 description 1
239000002581 neurotoxin Substances 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
230000003957 neurotransmitter release Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
239000002547 new drug Substances 0.000 description 1
238000010899 nucleation Methods 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
238000012261 overproduction Methods 0.000 description 1
230000004792 oxidative damage Effects 0.000 description 1
230000006919 peptide aggregation Effects 0.000 description 1
238000013146 percutaneous coronary intervention Methods 0.000 description 1
230000035699 permeability Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
238000011886 postmortem examination Methods 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
239000002243 precursor Substances 0.000 description 1
229960003387 progesterone Drugs 0.000 description 1
239000000186 progesterone Substances 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
230000009822 protein phosphorylation Effects 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
229960000996 pyrantel pamoate Drugs 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
208000008864 scrapie Diseases 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
238000010898 silica gel chromatography Methods 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
229960001471 sodium selenite Drugs 0.000 description 1
239000011781 sodium selenite Substances 0.000 description 1
235000015921 sodium selenite Nutrition 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
239000000758 substrate Substances 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
239000000725 suspension Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 1
229960001685 tacrine Drugs 0.000 description 1
102000013498 tau Proteins Human genes 0.000 description 1
108010026424 tau Proteins Proteins 0.000 description 1
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
238000003325 tomography Methods 0.000 description 1
125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000032258 transport Effects 0.000 description 1
201000008827 tuberculosis Diseases 0.000 description 1
208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
230000035899 viability Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/08—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
- C07C65/105—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic
- C07C65/11—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic with carboxyl groups on a condensed ring system containing two rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Emergency Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

SK1831-2002A 2000-06-23 2001-06-15 Derivát alebo analóg kyseliny pamoovej, spôsob jeho prípravy, farmaceutický prostriedok, diagnostická súprava a použitie SK18312002A3 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IT2000RM000340A IT1317048B1 (it)	2000-06-23	2000-06-23	Uso dell'acido pamoico o di un suo derivato, o di un suo analogo, perla preparazione di un medicamento per il trattamento di patologie
PCT/IT2001/000313 WO2002000603A1 (fr)	2000-06-23	2001-06-15	Utilisation de l'acide pamoique ou de l'un de ses derives ou analogues pour la preparation d'un medicament destine au traitement des maladies caracterisees par des depots d'agregats amyloides

Publications (1)

Publication Number	Publication Date
SK18312002A3 true SK18312002A3 (sk)	2003-06-03

Family

ID=11454799

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1831-2002A SK18312002A3 (sk)	2000-06-23	2001-06-15	Derivát alebo analóg kyseliny pamoovej, spôsob jeho prípravy, farmaceutický prostriedok, diagnostická súprava a použitie

Country Status (14)

Country	Link
US (3)	US20040029963A1 (fr)
EP (1)	EP1301463A1 (fr)
JP (1)	JP2004501893A (fr)
KR (1)	KR100764886B1 (fr)
CN (1)	CN1185210C (fr)
AU (1)	AU784980B2 (fr)
BR (1)	BR0111933A (fr)
CA (1)	CA2412568A1 (fr)
CZ (1)	CZ20024123A3 (fr)
IT (1)	IT1317048B1 (fr)
MX (1)	MXPA02012730A (fr)
PL (1)	PL360492A1 (fr)
SK (1)	SK18312002A3 (fr)
WO (1)	WO2002000603A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20080056221A (ko) *	2005-10-18	2008-06-20	시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이.	베타 아밀로이드 응집의 나프틸 유도체 억제제
CU23844B1 (es)	2009-04-17	2012-10-15	Ct De Neurociencias De Cuba	Procedimiento de obtención de nuevos derivados de naftaleno para el diagnóstico in vivo de la enfermedad de alzheimer
US9040583B2 (en) *	2009-07-22	2015-05-26	Temple University-Of The Commonwealth System Of Higher Education	Treatment of disorders associated with G protein-coupled receptor 35 (GPR35)
CN108685894B (zh)	2012-04-04	2022-04-26	英特维特国际股份有限公司	软咀嚼药用产品
CN102659577B (zh) *	2012-04-07	2014-07-02	安徽绩溪县徽煌化工有限公司	一种亚甲基双羟基萘酸的制备方法
RU2494750C1 (ru) *	2012-06-20	2013-10-10	Общество с ограниченной ответственностью "Научно-внедренческий центр Агроветзащита"	Способ получения стабилизированной формы антисептика-стимулятора дорогова - фракции 2 (асд-2)
CU20130027A7 (es)	2013-02-28	2014-10-30	Ct De Neurociencias De Cuba	Chaperoninas químicas como nuevos moduladores moleculares de la beta agregación proteica presente en las enfermedades conformacionales
CN106074476A (zh) *	2016-06-08	2016-11-09	天津大学	帕莫酸在制备BLyS拮抗剂的用途
EP3461488A1 (fr)	2017-09-27	2019-04-03	Onxeo	Combinaison d'une molécule dbait et un inhibiteur de hdac pour le traitement du cancer
EP3461480A1 (fr)	2017-09-27	2019-04-03	Onxeo	Combinaison d'inhibiteurs de point de contrôle du cycle cellulaire de réponse à un dommage à l'adn et de belinostat pour traiter le cancer
JP7478251B2 (ja) *	2019-12-14	2024-05-02	シャンハイイーストホスピタル（イーストホスピタル，トンジユニバーシティスクールオブメディシン）	イオンチャネルアンタゴニスト／遮断剤およびその用途
WO2021148581A1 (fr)	2020-01-22	2021-07-29	Onxeo	Nouvelle molécule dbait et son utilisation
EP4405680A1 (fr)	2021-09-20	2024-07-31	Institut National de la Santé et de la Recherche Médicale (INSERM)	Procédés pour l'amélioration de l'efficacité d'une thérapie par inhibiteur de hdac et la prédiction de la réponse à un traitement comprenant un inhibiteur de hdac
US20250213523A1 (en)	2022-04-05	2025-07-03	Istituto Nazionale Tumori Irccs - Fondazione G. Pascale	Combination of hdac inhibitors and statins for use in the treatment of pancreatic cancer
WO2025026925A1 (fr)	2023-07-28	2025-02-06	Ospedale San Raffaele S.R.L.	Inhibiteurs de gtf2i et leurs utilisations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU8897391A (en) *	1990-12-12	1992-06-18	Mitsubishi Kasei Corporation	Electrostatic image-developing toner
US5276059A (en) *	1992-07-10	1994-01-04	The United States Of America As Represented By The Department Of Health And Human Services	Inhibition of diseases associated with amyloid formation
IT1299544B1 (it) *	1998-07-03	2000-03-16	Sigma Tau Ind Farmaceuti	Composizioni solide atte alla somministrazione orale comprendenti sali non igroscopici della l-carnitina e delle alcanoil l-carnitine
EP0998946A1 (fr) *	1998-08-14	2000-05-10	K.U. Leuven Research & Development	Composés Non-Porphyriques à application diagnostique et/ou pharmaceutique
BR9904931A (pt) *	1999-10-18	2001-06-12	Sergio Teixeira Ferreira	Inibição de amiloidoses

2000
- 2000-06-23 IT IT2000RM000340A patent/IT1317048B1/it active
2001
- 2001-06-15 SK SK1831-2002A patent/SK18312002A3/sk not_active Application Discontinuation
- 2001-06-15 CZ CZ20024123A patent/CZ20024123A3/cs unknown
- 2001-06-15 AU AU69421/01A patent/AU784980B2/en not_active Ceased
- 2001-06-15 EP EP01947783A patent/EP1301463A1/fr not_active Withdrawn
- 2001-06-15 BR BR0111933-8A patent/BR0111933A/pt not_active IP Right Cessation
- 2001-06-15 WO PCT/IT2001/000313 patent/WO2002000603A1/fr not_active Ceased
- 2001-06-15 MX MXPA02012730A patent/MXPA02012730A/es not_active Application Discontinuation
- 2001-06-15 CN CNB018124461A patent/CN1185210C/zh not_active Expired - Fee Related
- 2001-06-15 KR KR1020027017421A patent/KR100764886B1/ko not_active Expired - Fee Related
- 2001-06-15 US US10/311,888 patent/US20040029963A1/en not_active Abandoned
- 2001-06-15 CA CA002412568A patent/CA2412568A1/fr not_active Abandoned
- 2001-06-15 PL PL36049201A patent/PL360492A1/xx not_active Application Discontinuation
- 2001-06-15 JP JP2002505352A patent/JP2004501893A/ja active Pending
2006
- 2006-05-11 US US11/431,831 patent/US20060205967A1/en not_active Abandoned
2007
- 2007-11-01 US US11/979,301 patent/US20080293812A1/en not_active Abandoned

Also Published As

Publication number	Publication date
WO2002000603A1 (fr)	2002-01-03
CZ20024123A3 (cs)	2003-05-14
CN1449375A (zh)	2003-10-15
MXPA02012730A (es)	2003-05-14
PL360492A1 (en)	2004-09-06
KR20030017554A (ko)	2003-03-03
AU784980B2 (en)	2006-08-17
ITRM20000340A0 (it)	2000-06-23
KR100764886B1 (ko)	2007-10-09
CA2412568A1 (fr)	2002-01-03
US20060205967A1 (en)	2006-09-14
IT1317048B1 (it)	2003-05-26
CN1185210C (zh)	2005-01-19
EP1301463A1 (fr)	2003-04-16
US20040029963A1 (en)	2004-02-12
JP2004501893A (ja)	2004-01-22
US20080293812A1 (en)	2008-11-27
AU6942101A (en)	2002-01-08
BR0111933A (pt)	2003-06-17
HK1058515A1 (en)	2004-05-21
ITRM20000340A1 (it)	2001-12-23

Legal Events

Date	Code	Title	Description
2010-04-07	FC9A	Refused patent application

Publication	Publication Date	Title
US20080293812A1 (en)	2008-11-27	Use of pamoic acid or one of its derivatives, or one of its analogues, for the preparation of a medicament for the treatment of diseases characterised by deposits of amyloid aggregates
C Bell et al.	2016	PERK-opathies: an endoplasmic reticulum stress mechanism underlying neurodegeneration
US8911707B2 (en)	2014-12-16	Thioflavin derivatives for use in antemortem diagnosis of alzheimer's disease and in vivo imaging and prevention of amyloid deposition
KR20010031872A (ko)	2001-04-16	알츠하이머 병을 죽기 전에 진단하고, 아밀로이드 침적을생체내에서 단층촬영하고 예방하기 위한 화합물
WO1998040071A1 (fr)	1998-09-17	Identification d'agents utiles dans le traitement de la maladie d'alzheimer
WO1998040071A9 (fr)	1999-02-25	Identification d'agents utiles dans le traitement de la maladie d'alzheimer
CN106458866B (zh)	2018-12-07	氨基羰基氨基甲酸酯化合物
EP2120557A2 (fr)	2009-11-25	Composés de polyhydroquinoléine et composés de dihydropyridine servant à inhiber la production de bêta-amyloïdes
WO2014179303A1 (fr)	2014-11-06	Bloqueurs de l'arn messager de protéine précurseur de l'amyloïde permettant de traiter le syndrome de down et la maladie d'alzheimer
CA3120639A1 (fr)	2020-05-28	Compositions et methodes de traitement de troubles neurodegeneratifs, myodegeneratifs et du stockage lysosomal
HUP0301205A2 (hu)	2003-11-28	Pamoesav, származékai és analógja alkalmazása amiloid aggregátumok lerakódásával jellemzett betegségek kezelésére alkalmas gyógyszerkészítmény előállítására és eljárás a vegyületek előállítására
KR20080056221A (ko)	2008-06-20	베타 아밀로이드 응집의 나프틸 유도체 억제제
CN101730565B (zh)	2015-06-10	取代膦酸酯及其用于减少淀粉样聚集物的用途
RU2566757C2 (ru)	2015-10-27	Арилфторфосфатные ингибиторы кишечного апикального мембранного натрий/фосфатного котранспорта
JP2011518188A (ja)	2011-06-23	リソソーム調節のための化合物および使用方法
Chen et al.	2022	Design, synthesis, and evaluation of 8-aminoquinoline-melatonin derivatives as effective multifunctional agents for Alzheimer’s disease
KR102681183B1 (ko)	2024-07-04	나트륨-수소 교환기 3 억제제 화합물
CN108727350A (zh)	2018-11-02	一类哌啶烷基苯酞类化合物、其制备方法和用途
AU2006220097A1 (en)	2006-09-08	Derivatives of aminobutanoic acid inhibiting CPT
US20150217004A1 (en)	2015-08-06	Carbamate compounds and methods of use in diseases of the nervous system
CN121673256A (zh)	2026-03-17	一种取代香豆素-丁香酚衍生物及其制备方法和应用
HK1125056A (en)	2009-07-31	Naphthyl derivatives as inhibitors of beta-amyloid aggregation
HK1075245A (en)	2005-12-09	Novel adamantane derivatives with neuroprotective, antidepressant and anti-ischaemic activities, and process for preparing them